Additional Information
Market: NASDAQ
Sector: Pharmaceuticals & Biotech
Latest Price: 12.64  (4.64% Ascending)
52-week High: 26.35
52-week Low: 10.90
Market Cap: 478.88M
1 year chart
1 day chart

Omeros Corporation is a clinical-stage biopharmaceutical company. It is engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.

Omeros shares spike on successful phase 3 trial for lens replacement surgery drug

13th Mar 2012, 9:53 am by Olivia D'Orazio
Omeros shares spike on successful phase 3 trial for lens replacement surgery drug

Omeros (NASDAQ:OMER) saw its stock rise more than 22 percent Tuesday morning, following news that its OMS302 drug achieved both primary and secondary goals in a phase three study.

The phase three, placebo-controlled trial investigated the drug for the treatment of patients undergoing intraocular lens replacement surgery.

On the Nasdaq Exchange, shares of the company rose 22.12 percent to $9.33, as of 9:45 am EDT.

The OMS302 drug met its primary endpoint, by demonstrating a statistically significant maintenance of intraoperative mydriasis, or pupil dilation. OMS302 also demonstrated "superior pain reduction", the study's secondary endpoint, compared to placebo.

"This is an important day for Omeros," said CEO, Dr. Gregory A. Demopulos.

"This achievement marks our transition to a company preparing, rather than hoping, to commercialize our first product. Following our recent successful meetings with U.S. and European regulators, we plan to begin enrolling patients in our second Phase 3 trial early next month and to submit marketing applications in both the U.S. and Europe in the first part of 2013."

The OMS302 drug consists of a combination of an anti-inflammatory active pharmaceutical ingredient (API) and an API that causes pupil dilation. Each API involved has well-known safety and pharmacologic properties, Omeros said.

During the multi-centre, double-blind, phase three trial, 405 patients were randomized to receive either the OMS302 drug or a placebo. The drug, or placebo, was added to the standard irrigation solution during the surgery, in order to maintain mydriasis and reduce post-operative pain.

Director of glaucoma and cataract at the Moran Eye Center of the University of Utah, Dr. Alan S. Crandall, said: "The data from this study are compelling and demonstrate that OMS302 addresses a universal need in lens replacement surgery.

"Ophthalmologic surgeons are committed to successful outcomes for their patients, and maintenance of mydriasis and pain management are central to that success. Given the drug's demonstrated effects on these two challenges facing all lens replacement surgeons, I expect that OMS302 could become widely used."

Based in Seattle, Washington, the clinical-stage biopharmaceutical company focuses on products aimed at inflammation, bleeding and disorders of the central nervous system.

Omeros uses its PharmacoSurgery platform, which is designed to deliver low-dose drugs directly to the surgical site, pre-emptively reducing inflammation and other problems caused by surgery.

No investment advice

Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here